Drug intelligence / Profile preview

CGEN-857

Development stage: Unknown
Lead developer: Compugen
Modality: Peptides

Overview

CGEN-857 is a novel peptide designed by Compugen Ltd. It is part of a collaborative partnership with DiscoveRx Corporation, where DiscoveRx utilizes its PathHunter Platform and proprietary cell-based GPCR assays to match Compugen's peptides with specific G protein-coupled receptor (GPCR) targets. Once matched, these peptides, including CGEN-857, are intended for licensing to pharmaceutical clients under milestone and royalty agreements. This partnership aims to leverage GPCRs as significant drug targets and advance Compugen's discoveries without extensive internal funding.

Targets

MRGPR (Mas-related G protein-coupled receptor family)

Beyond the preview

Go deeper on CGEN-857.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGEN-857.

Explore the full profile